Novartis Lescol May Be OTC Switch Candidate, Karabelas Says
The safety profile of Novartis' HMG-CoA reductase inhibitor Lescol would support an OTC switch, Novartis Pharmaceuticals CEO Jerry Karabelas suggested at a review of the company's 1997 financial results held March 17 in London.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth